The future of cytotoxic therapy: selective cytotoxicity based on biology is the key
about
A molecular analysis by gene expression profiling reveals Bik/NBK overexpression in sporadic breast tumor samples of Mexican femalesA chemocentric approach to the identification of cancer targetsAndrogen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?A review on various targeted anticancer therapies.Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure.Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer.Reversing resistance to targeted therapy.Target for cancer therapy: proliferating cells or stem cells.The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by activating MEK/ERK mediated RARα/STAT1 axis.Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort studyPoly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.MET inhibition in lung cancer.Prognostic Impact of Progesterone Receptor Status in Chinese Estrogen Receptor Positive Invasive Breast Cancer Patients.Future directions in the evaluation of c-MET-driven malignancies.Androgen Receptor Expression in an Indian Breast Cancer Cohort with Relation to Molecular Subtypes and Response to Neoadjuvant Chemotherapy - a Prospective Clinical Study.
P2860
Q24810612-7E510BE6-4EAE-4A3A-8549-7D9840E34F46Q28482507-00D1FDCF-DE6F-42C0-9267-4422F7B5BEA4Q33932665-27D70045-3319-4638-B5AC-601700FD521BQ34164735-0594D1C5-CF9C-4931-A2C5-4E6DDD1C6C77Q34335039-C2C5F59C-E2A1-4B40-B502-D136059414ADQ34607218-7B0EB401-4D3C-4219-9019-C950D198FF49Q36028603-7FC8772D-B1FF-4DB6-9EE1-623519DBF12CQ36343524-0527EE32-350E-4344-B133-51CC7644A96FQ36796264-4764F138-3147-4B88-B23F-768682271CF2Q37548507-6601EED3-F308-4CC0-B0BB-CAACED324FD5Q37826009-8C03572D-323D-4D6F-B101-1F0BC25F476BQ38390016-BC9DE0A3-0005-4434-8F36-5CD0E8F76550Q38687389-61590C84-B8F9-4667-95B7-D597E6F97047Q39405818-E0D16D12-2E40-40EE-99B0-715920D81CECQ55431963-DC1527C3-E5C1-4863-B60E-4B88F3F88469
P2860
The future of cytotoxic therapy: selective cytotoxicity based on biology is the key
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The future of cytotoxic therapy: selective cytotoxicity based on biology is the key
@ast
The future of cytotoxic therapy: selective cytotoxicity based on biology is the key
@en
The future of cytotoxic therapy: selective cytotoxicity based on biology is the key
@nl
type
label
The future of cytotoxic therapy: selective cytotoxicity based on biology is the key
@ast
The future of cytotoxic therapy: selective cytotoxicity based on biology is the key
@en
The future of cytotoxic therapy: selective cytotoxicity based on biology is the key
@nl
prefLabel
The future of cytotoxic therapy: selective cytotoxicity based on biology is the key
@ast
The future of cytotoxic therapy: selective cytotoxicity based on biology is the key
@en
The future of cytotoxic therapy: selective cytotoxicity based on biology is the key
@nl
P2093
P2860
P3181
P356
P1476
The future of cytotoxic therapy: selective cytotoxicity based on biology is the key
@en
P2093
Anthony W Tolcher
Eric K Rowinsky
Johann S de Bono
P2860
P2888
P3181
P356
10.1186/BCR597
P407
P577
2003-03-27T00:00:00Z
P5875
P6179
1024352049